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Background: An inhaled corticosteroid (ICS) or leukotriene receptor antagonist (LTRA) may 
prevent wheezing/asthma attacks in preschoolers with recurrent wheeze when added to short-
acting β-agonist (SABA).
Objective: The aim of this historical matched cohort study was to assess the effectiveness of 
these treatments for preventing wheezing/asthma attacks.
Methods: Electronic medical records from the Optimum Patient Care Research Database were 
used to characterize a UK preschool population (1–5 years old) with two or more episodes of 
wheezing during 1 baseline year before first prescription (index date) of ICS or LTRA, or repeat 
prescription of SABA. Children initiating ICS or LTRA on the index date were matched 1:4 
to those prescribed only SABA for age, sex, year of index prescription, mean baseline SABA 
dose, baseline attacks, baseline antibiotic prescriptions, and eczema diagnosis. Wheezing/
asthma attacks (defined as asthma-related emergency attendance, hospital admission, or acute 
oral corticosteroid prescription) during 1 outcome year were compared using conditional logistic 
regression.
Results: Matched ICS and SABA cohorts included 990 and 3,960 children, respectively (61% 
male; mean [SD] age 3.2 [1.3] years), and matched LTRA and SABA cohorts included 259 
and 1,036 children, respectively (65% male; mean [SD] age 2.6 [1.2] years). We observed no 
significant difference between matched cohorts in the odds of a wheezing/asthma attack: ICS 
vs SABA, OR (95% CI) 1.01 (0.85–1.19) and LTRA vs SABA, OR (95% CI) 1.28 (0.96–1.72).
Conclusion: We found no evidence that initiation of ICS or LTRA therapy is associated with 
fewer attacks during 1 outcome year than SABA alone for a heterogeneous group of preschool 
children with recurrent wheeze in the real-life clinical setting.
Keywords: electronic medical records, inhaled corticosteroids, leukotriene receptor antagonists, 
observational study, ICS particle size, short-acting β-agonist
Introduction
Acute episodes of asthma-like symptoms (wheezing/asthma attacks) are common in 
preschool children, affecting as many as one-third to one-half of children in the US 
and Western Europe at least once in their first 6 years.1–3 The associated health care 
burden is substantial, with children aged 1–5 years comprising the majority of children 
presenting to hospitals and emergency departments (EDs)  in the US and UK with an 
attack of wheezing/asthma.4,5
The optimal approach for preventing recurrent episodes of wheezing/asthma in 
preschool children remains an active area of study and debate.6–9 International and UK 
asthma management guidelines provide little definitive guidance for recurrent attack 
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prevention in this age group.10,11 Wheezing phenotypes are 
heterogeneous and can change over time in an individual 
child.12,13 The results of landmark clinical trials indicate that 
for children at high risk of developing persistent asthma (ie, 
with positive asthma predictive index [API])14,15 who are 
asymptomatic between wheezing episodes, therapy with daily 
low-dose or intermittent (as needed) high-dose ICS reduces 
attack rate as well as symptom burden during attacks.16–18 
More recently, a meta-analysis of randomized controlled 
trials (RCTs) found strong evidence to support intermittent 
ICS therapy for preschool children with intermittent asthma 
or viral-triggered wheeze.8 In addition, a recent study found 
no overall benefit of intermittent therapy with montelukast, a 
leukotriene receptor antagonist (LTRA), in preschool wheeze, 
albeit that need for rescue oral corticosteroid (OCS)  (a sec-
ondary outcome) was reduced.19 Overall, however, common 
conclusions from these studies are the marked heterogeneity 
of response and need for further studies.16–20
Studying preschool children is challenging both because 
of diagnostic and therapeutic limitations and because of the 
ethical issues and difficulties associated with enrolling suf-
ficient numbers of children into clinical trials.21 Furthermore, 
strict trial eligibility criteria and the unique ecology of care 
provided in RCTs may limit the applicability of RCT results 
to the unselective and less controlled environment of every-
day clinical practice, where frequent follow-up, extensive 
education of parents and children, and optimized adherence 
to therapy are often not feasible.22,23
Observational studies using anonymized medical record 
data can complement and supplement RCT results by enabling 
the study of large groups over long periods.22,24 In a prior 
matched cohort study of children with asthma (ages 5–11) 
years, we found evidence of better effectiveness of extrafine 
(EF)-particle ICS (mass median aerodynamic diameter 
[MMAD] <2 µm) as compared with fine-particle ICS (MMAD 
≥2 µm).25 This led us to speculate that administration of an EF-
particle ICS could also be more beneficial for the youngest 
children. Of note, almost all prior RCTs of preschool children 
used a fine-particle (rather than an EF-particle) ICS formula-
tion, most commonly fluticasone propionate or budesonide.8
The aims of this historical matched cohort study were 
to compare outcomes for a broad general UK population 
of preschool children with evidence of prior wheezing who 
remained on either as-needed short-acting β-agonist (SABA) 
or stepped up to controller therapy (plus as-needed SABA), 
as either ICS or LTRA. In addition, we compared outcomes 
with the two controller therapies (ICS vs LTRA) and tested 
the hypothesis that use of EF-particle ICS would be associ-
ated with better outcomes than fine-particle ICS.
Methods
Data source and study approval
At the time of this study, the Optimum Patient Care Research 
Database contained anonymized, longitudinal medical record 
data for 2.5 million patients in the UK, where patients’ elec-
tronic medical records, incorporating primary, secondary, 
and hospitalization care data, are centralized at their primary 
care practices.26 The study was conducted in compliance 
with all applicable local and international regulations and 
to standards suggested for observational studies (details in 
the Supplementary materials).27 The protocol, analyses, and 
dissemination of the results were approved by an independent 
steering committee of the Respiratory Effectiveness Group,28 
a not-for-profit research and advocacy organization dedicated 
to furthering real-life clinical research.
study design and patients
This was a matched cohort analysis employing a total of four 
two-way matched comparisons: 1) all ICSs by pressurized 
metered-dose inhaler (pMDI)  vs SABA, 2) LTRA vs SABA, 
3) LTRA vs all ICSs by pMDI, and 4) EF-particle ICS vs 
fine-particle ICS by pMDI. We studied two consecutive years 
of data for each child, including 1 baseline year for clinical 
characterization leading up to the index date, followed by 1 
outcome year (Figure 1). The index date was defined as the 
time of either a first prescription for asthma controller therapy 
(listed below) or a repeat prescription for SABA.
Children eligible for the study were ≥1 year and up to 5 
years of age at the index date and during the baseline year 
had two or more wheezing episodes (described in diagnostic 
Read codes in the Supplementary materials) or two or more 
prescriptions (at different points in time) for any combination 
of OCS, with or without concomitant SABA, with accom-
panying code for a lower respiratory complaint. During the 
outcome year, children had to have at least one additional 
prescription for any asthma controller therapy (the same as or 
different from the index prescription) or two or more SABA 
prescriptions (SABA control arms).
Children <1 year old were excluded to ensure 1 full year 
of baseline data. Other exclusion criteria were any chronic 
respiratory disease other than wheeze/asthma, ICS or LTRA 
prescription during the baseline year, combination LABA–
ICS prescription during the baseline year or on the index date, 
or multiple step-up therapies on the index date. The study 
period was from January 1988 to May 2015.
Asthma controller therapies included as index date 
prescriptions were EF-particle ICS delivered by pMDI 
(ciclesonide or EF-particle beclomethasone [Qvar®; Teva UK 
Ltd., Castleford, UK]), fine-particle ICS delivered by pMDI 
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(fluticasone, budesonide, or fine-particle beclomethasone 
[Clenil® Modulite®; Chiesi Ltd., Manchester, UK]), and 
LTRAs. Children belonging to the SABA arms (but not those 
in controller therapy arms) were required to have at least 
one SABA prescription during the baseline year before the 
index date; the index date SABA prescription for the study 
was identified through the matching process as providing the 
best match. Therapy could change during the outcome year 
as prescribed by the health care provider.
Outcome measures
The primary study end point was a wheezing/asthma attack, 
defined according to the American Thoracic Society/
European Respiratory Society criteria for a severe asthma 
exacerbation as any of the following: an asthma-related 
ED attendance, an asthma-related hospital admission, or an 
OCS prescription coded for asthma or wheeze.29 We note 
that this measure differed from the baseline year wheezing 
episodes applied as a study eligibility criterion, which we 
defined according to diagnostic Read codes (Supplementary 
materials) and for which the definition did not necessarily 
include an asthma-related ED attendance, hospital admission, 
or OCS prescription.
Secondary end points, defined in Table S1, included 
acute respiratory events, risk-domain asthma control, and 
treatment stability, composite end points utilized in prior 
studies by the authors.25,30,31 Exploratory outcome measures 
included oral candidiasis (thrush) and time to first wheezing/
asthma attack.
We calculated daily SABA dose by averaging the number 
of doses in issued prescriptions during each study year, with 
one dose defined as two puffs (200 µg). Similarly, the aver-
age daily ICS dose exposure during the outcome year was 
calculated using the total ICS dose in prescriptions during 
the outcome year divided by 365 days. The doses of ICS were 
standardized to equivalence with fluticasone propionate; thus, 
the actual doses of fluticasone and EF-particle beclometha-
sone were used, and doses of budesonide and fine-particle 
beclomethasone were halved.
statistical analysis
Children in each set of two comparison cohorts were matched, 
at ratios selected to maximize statistical power, sequentially 
for the following key demographic and baseline year clini-
cal characteristics (details in the Supplementary materials): 
age (years) at the index date, sex, index date year, mean 
daily SABA doses, wheezing/asthma attacks (yes/no), acute 
antibiotic prescriptions (yes/no), and ever-recorded eczema 
(yes/no).
The four sets of two matched cohorts were compared 
for baseline characteristics and binary outcome measures 
using conditional logistic regression. Kaplan–Meier curves 
for time to first wheezing/asthma attack were produced for 
each matched cohort comparison, and the time to first attack 
was compared using a stratified log-rank test for equality of 
 survivor curves across matched cohorts. Children who experi-
enced treatment failure before a first wheezing/asthma attack 
were censored at 7 days after the date of treatment failure, 
Figure 1 study schematic.
Notes: The eligibility criterion of two or more Ocs prescriptions (at different points in time) could be for any combination of Ocs, with or without concomitant sABA, 
with accompanying code for a lower respiratory complaint. aPrescribed therapy could change during the outcome year after the index date.
Abbreviations: ics, inhaled corticosteroid; lTrA, leukotriene receptor antagonist; Ocs, oral corticosteroid; sABA, short-acting β-agonist.
Index date:
Date of repeat SABA (control arm) 
or first ICS or LTRA prescription
Baseline year
12 months before index date for 
patient characterization
Eligibility criteria:
• Evidence of  ≥2 episodes of 
wheezing and/or ≥2 OCS 
prescriptions during baseline year
• Age: at least 1 year and ≤5 years 
on the index date
SABAa
LTRA ± SABAa
ICS ± SABAa
Outcome year
12 months after the index date for 
outcome evaluation
± SABA
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defined as addition of new therapy or ≥50% increase in dose 
of index date therapy. Treatment failure was included as a 
variable only in the Kaplan–Meier analyses (further informa-
tion is provided in the Supplementary materials).
Matching was completed using SAS version 9.3 (SAS 
Institute, Cary, NC, USA). Outcome analyses were carried 
out using Stata version 14.1 (StataCorp LLC, College Sta-
tion, TX, USA).
Results
Patients
Children who met eligibility criteria numbered 11,329 in 
the ICS cohort, 335 in the LTRA cohort, and 12,373 in 
the SABA cohort. Figures S1–S4 depict the numbers of 
children (or medical records in the case of SABA) retained 
Table 1 Baseline year characteristics of children included in the controller (ics or lTrA) vs sABA matched cohort comparisons
Characteristics ICS vs SABA LTRA vs SABA
ICS (n=990) SABA (n=3,960) LTRA (n=259) SABA (n=1,036)
Male sex, n (%)a 602 (60.8) 2,408 (60.8) 168 (64.9) 672 (64.9)
Age at index date (years), mean (sD)a 3.2 (1.3) 3.2 (1.3) 2.6 (1.2) 2.6 (1.2)
comorbidity, n (%)b
eczemaa 372 (37.6) 1,488 (37.6) 97 (37.5) 388 (37.5)
rhinitis 36 (3.6) 170 (4.3) 11 (4.3) 35 (3.4)
Total wheezing/asthma attacks, n (%)a
0 635 (64.1) 2,540 (64.1) 134 (51.7) 536 (51.7)
≥1 355 (35.9) 1,420 (35.9) 125 (48.3) 500 (48.3)
Ocs courses, n (%)
0 656 (66.3) 2,657 (67.1) 147 (56.8) 582 (56.2)
1 222 (22.4) 884 (22.3) 59 (22.8) 293 (28.3)
2 78 (7.9) 320 (8.1) 30 (11.6) 115 (11.1)
≥3 34 (3.4) 99 (2.5) 10 (3.9) 9 (0.9)
≥1 wheezing/asthma attack and ≥1 acute Ocs course 334 (33.7) 1,303 (32.9) 112 (43.2) 454 (43.8)
Acute antibiotic prescriptions, n (%)a
0 510 (51.5) 2,040 (51.5) 105 (40.5) 420 (40.5)
1 235 (23.7) 981 (24.8) 59 (22.8) 293 (28.3)
2 129 (13.0) 539 (13.6) 54 (20.9) 180 (17.4)
≥3 116 (11.7) 400 (10.1) 21 (8.1) 58 (5.6)
Mean (sD) daily no. of sABA dosesa,c 0.65 (0.56) 0.65 (0.47) 0.66 (0.50) 0.66 (0.49)
Median (iQr) daily no. of sABA dosesc 0.55 (0.55–0.82) 0.55 (0.55–0.82) 0.55 (0.55–0.82) 0.55 (0.55–0.82)
hospital admission, ≥1, n (%) 36 (3.7) 157 (4.0) 21 (8.1) 64 (6.2)e
eD attendance, ≥1, n (%) 13 (1.3) 52 (1.3) 19 (7.3) 20 (2.0)
Acute respiratory event, ≥1, n (%)d 617 (62.3) 2,468 (62.3) 193 (74.5) 772 (74.5)
risk-domain asthma control, n (%)d 373 (37.7) 1,492 (37.7) 66 (25.5) 264 (25.5)
Oral candidiasis, ≥1, n (%)d 11 (1.1) 55 (1.4) 7 (2.7) 26 (2.5)
Pneumonia, yes, n (%)d 12 (1.2) 43 (1.1) 9 (3.5) 8 (0.8)e
Notes: aMatching variable. Wheezing/asthma attacks were defined as any of the following: an asthma-related ED attendance, an asthma-related hospital admission, or an 
Ocs prescription coded for asthma or wheeze. bComorbidities were defined as follows: eczema as ever-recorded diagnostic Read code + topical corticosteroid; and rhinitis, 
as ever-recorded diagnosis and/or prescription for nasal corticosteroids. cThe daily sABA dose was calculated as the number of doses in issued prescriptions averaged over 
the baseline year. One sABA dose was two puffs (100 µg per puff). dAn acute respiratory event was defined as occurrence of 1) an asthma-related hospital admission or ED 
attendance or 2) an acute course of OCSs coded for asthma or 3) antibiotics prescribed with a lower respiratory consultation. Risk-domain asthma control was defined as 
follows: 1) no asthma-related hospital admission, eD attendance, or outpatient department attendance; 2) no acute Ocs prescription with a lower respiratory consultation; 
and 3) no antibiotics prescribed with a lower respiratory consultation (Table S1). Oral candidiasis (thrush) was defined as a Read code for oral candidiasis or topical antifungal 
prescription definitely for treating oral candidiasis. Pneumonia was defined as a diagnostic Read code for pneumonia. eP≤0.001 for comparison between lTrA and sABA 
cohorts. There were no significant differences between ICS and SABA cohorts or between LTRA and SABA cohorts for other variables.
Abbreviations: eD, emergency department; ics, inhaled corticosteroid; iQr, interquartile range; lTrA, leukotriene receptor antagonist; Ocs, oral corticosteroid; sABA, 
short-acting β-agonist.
at each step of the matching process for the four two-way 
comparisons.
controller therapy versus sABA
Patients
The ICS and LTRA cohorts were each matched in 1:4 ratio 
to the SABA cohort, resulting in 990:3,960 (ICS:SABA) 
and 259:1,036 (LTRA:SABA) children in the two analyses 
(Figures S1 and S2). In the ICS vs SABA comparison, 61% 
of children were male and the mean age was 3.2 years; in 
the LTRA vs SABA comparison, 65% of children were male 
and the mean age was 2.6 years. The prevalence of recorded 
eczema was 38% in each of the four cohorts (Table 1).
Overall, 36% of children in the matched ICS/SABA 
cohorts had experienced one or more wheezing/asthma 
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attacks during the baseline year. In the matched LTRA/
SABA cohorts, 48% of children had experienced one or 
more attacks during the baseline year, including 24% and 
17% in LTRA and SABA cohorts, respectively, who had 
experienced two or more attacks. Approximately half of 
children in the matched ICS/SABA cohorts and 60% of 
children in the matched LTRA/SABA cohorts had received 
one or more antibiotic prescriptions during the baseline 
year (Table 1).
Figure 2 Forest plot depicting Or (95% cis) of wheezing/asthma attack for the four matched cohort comparisons.
Notes: The reference cohort (attack odds =1.0) is listed second. EF: EF particle; fine: fine particle.
Abbreviations: EF, extrafine; ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist; SABA, short-acting β-agonist.
0.77 (0.43–1.38)
1.15 (0.85–1.53)
1.28 (0.96–1.72)
1.01 (0.85–1.19)
EF vs fine ICS
ICS vs LTRA
LTRA vs SABA
ICS vs SABA
0.1 1.0 10
Fewer attacks  More attacks
Odds ratio
Table 2 Outcome measures during 1 follow-up year for the controller (ics or lTrA) vs sABA matched cohort comparisons
Outcome ICS vs SABA LTRA vs SABA
ICS (n=990) SABA (n=3,960) P-valuea LTRA (n=259) SABA (n=1,036) P-valuea
Wheezing/asthma attack, n (%)
0 728 (73.5) 2,918 (73.7) 0.92 157 (60.6) 682 (65.8) 0.097
1 161 (16.3) 649 (16.4) 54 (20.9) 216 (20.9)
≥2 101 (10.2) 393 (9.9) 48 (18.5) 138 (13.3)
hospital admission, n (%)
0 975 (98.5) 3,884 (98.1) 0.40 251 (96.9) 1,002 (96.7) 0.88
1 12 (1.2) 67 (1.7) 6 (2.3) 28 (2.7)
≥2 3 (0.3) 9 (0.2) 2 (0.8) 6 (0.6)
eD visit, n (%)
0 969 (97.9) 3,921 (99.0) 0.004 252 (97.3) 1,022 (98.7) 0.13
1 19 (1.9) 37 (0.9) 5 (1.9) 12 (1.2)
2 0 (0) 2 (0.1) 2 (0.8) 2 (0.2)
3 2 (0.2) 0 (0) 0 0
Acute Ocs prescription, n (%)
0 814 (82.2) 3,250 (82.1) 0.91 164 (63.3) 703 (67.9) 0.14
1 128 (12.9) 509 (12.9) 46 (17.8) 206 (19.9)
2 33 (3.3) 144 (3.6) 23 (8.9) 77 (7.4)
3 8 (0.8) 45 (1.1) 0 0
4 6 (0.6) 10 (0.3) 4 (1.5) 9 (0.9)
≥5 1 (0.1) 1 (0.0) 3 (1.2) 0
Note: aMatched cohorts were compared (for none vs ≥1 outcome) using conditional logistic regression.
Abbreviations: eD, emergency department; ics, inhaled corticosteroid; lTrA, leukotriene receptor antagonist; Ocs, oral corticosteroid; sABA, short-acting β-agonist.
The median (IQR) dose of ICS prescribed on the index 
date was fluticasone-equivalent 100 (100–200) µg/day 
(budesonide-equivalent dose, 200 [200–400] µg/day).
Outcomes
There was no significant difference in the odds of a wheezing/
asthma attack during the outcome year between the matched 
cohorts in either of the two comparisons between controller 
therapy and SABA (Figure 2; Table 2). During the outcome 
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year, 26% of children in the matched ICS/SABA cohorts 
experienced one or more attacks; and in the matched LTRA/
SABA comparison, 39% and 34% of children in LTRA and 
SABA cohorts, respectively, experienced one or more attacks 
(Figure 3; Table 2). Fewer children experienced attacks during 
the outcome than the baseline year (Figure 3).
A significantly higher percentage of children in the ICS 
cohort (2.1%) vs the matched SABA cohort (1.0%) expe-
rienced one or more ED visits (P=0.004). There were no 
other significant differences between the two sets of matched 
cohorts in secondary outcome measures (Tables 2 and S2).
In the matched ICS/SABA comparison, 1,986 (50%) 
children in the SABA cohort were prescribed ICS at some 
point during the outcome year. In the matched LTRA/SABA 
comparison, 162 (63%) and 521 (50%) children in LTRA and 
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Figure 3 (Continued)
SABA cohorts, respectively, were prescribed ICS during the 
outcome year.
The time to first wheezing/asthma attack was similar in 
the two comparisons (log-rank P>0.10; Figures S5 and S6).
comparisons of controller therapies
Patients
The LTRA and ICS cohorts were matched 1:1, resulting 
in 104 children in each cohort (Figure S3); the EF-particle 
ICS and fine-particle ICS cohorts were matched 1:4, result-
ing in 275 and 1,100 children in each cohort, respectively 
(Figure S4). In the matched LTRA/ICS comparison, 61% 
of children were male and mean age was 2.6 years; in the 
matched EF-particle ICS/fine-particle ICS comparison, 68% 
of children were male and mean age was 3.2 years (Table 3). 
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Figure 3 Percentage of children with one or more wheezing/asthma attacks during the baseline year (before the first prescription of ICS, LTRA, or repeat SABA) and during 
the outcome year in the four matched cohort comparisons: (A) ics ± sABA vs sABA, (B) lTrA ± SABA vs SABA, (C) LTRA vs ICS, and (D) EF-particle ICS vs fine-particle 
ics.
Notes: A wheezing/asthma attack was defined as an asthma-related ED attendance, an asthma-related hospital admission, or an OCS prescription coded for asthma or 
wheeze. EF: EF particle; fine: fine particle.
Abbreviations: ED, emergency department; EF, extrafine; ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; SABA, short-acting 
β-agonist.
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The prevalence of recorded eczema was 38% in matched 
LTRA/ICS cohorts and 41% in matched EF-particle ICS/
fine-particle ICS cohorts.
During the baseline year, one or more wheezing/asthma 
attacks were recorded for 72% of children in the matched 
LTRA/ICS cohorts and 52% of children in the matched EF-
particle ICS/fine-particle ICS cohorts (Table 3). Approxi-
mately 71% of children in matched LTRA/ICS cohorts and 
55% of children in matched EF-particle ICS/fine-particle 
ICS cohorts had received one or more antibiotic prescriptions 
during the baseline year (Table 3).
On the index date, the prescribed median (IQR) fluti-
casone-equivalent dose was 100 (100–100) µg/day in the 
ICS cohort of the matched LTRA/ICS comparison and 100 
(100–100) and 200 (100–200) µg/day in matched EF-particle 
ICS and fine-particle ICS cohorts, respectively.
Outcomes
There was no significant difference in the odds of a wheezing/
asthma attack during the outcome year between the matched 
cohorts in either of the two controller therapy comparisons 
(Figure 2; Table 4). In the matched LTRA/ICS cohorts, 45% 
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and 39% of children, respectively, experienced one or more 
attacks; in the matched EF-particle ICS/fine-particle ICS 
cohorts, 36% and 33% of children, respectively, experienced 
one or more attacks (Figure 3; Table 4). Overall, fewer 
children experienced attacks during the outcome than the 
baseline year (Figure 3).
There were no statistically significant differences between 
matched cohorts for either of the two controller therapy 
comparisons during the outcome year (Tables 4 and S3).
Seventy-two (69%) children in the LTRA cohort were 
prescribed ICS and eight (8%) children in the ICS cohort 
were prescribed LTRA during the outcome year.
Table 3 Baseline year characteristics of children included in the two controller therapy matched cohort comparisons: lTrA vs ics 
and EF-particle ICS vs fine-particle ICS
Characteristics LTRA vs ICS EF-particle ICS vs fine-particle ICS
LTRA  
(n=104)
ICS  
(n=104)
EF-particle ICS  
(n=275)
Fine-particle ICS  
(n=1,100)
Male sex, n (%)a 63 (60.6) 63 (60.6) 186 (67.6) 744 (67.6)
Age at index date (years), mean (sD)a 2.6 (1.1) 2.6 (1.1) 3.2 (1.2) 3.2 (1.2)
comorbidity, n (%)b
eczemaa 39 (37.5) 39 (37.5) 113 (41.1) 452 (41.1)
rhinitis 6 (5.8) 7 (6.7) 10 (3.6) 41 (3.7)
Total wheezing/asthma attacks, n (%)a
0 29 (27.9) 29 (27.9) 133 (48.4) 532 (48.4)
≥1 75 (72.1) 75 (72.1) 142 (51.6) 568 (51.6)
Ocs courses, n (%)
0 35 (33.7) 32 (30.8) 140 (50.9) 565 (51.4)
1 41 (39.4) 41 (39.4) 86 (31.3) 340 (30.9)
2 20 (19.2) 20 (19.2) 36 (13.1) 128 (11.6)
≥3 8 (7.7) 11 (10.6) 13 (4.7) 67 (6.1)
≥1 wheezing/asthma attack and ≥1 
acute Ocs course
69 (66.3) 72 (69.2) 135 (49.1) 535 (48.6)
Acute antibiotic prescriptions, n (%)a
0 30 (28.9) 30 (28.9) 123 (44.7) 492 (44.7)
1 33 (31.7) 29 (27.9) 72 (26.2) 280 (25.5)
2 20 (19.2) 16 (15.4) 49 (17.8) 183 (16.6)
≥3 21 (20.2) 29 (27.9) 31 (11.3) 145 (13.2)
Mean (sD) daily no. of sABA dosesa,c 0.47 (0.27) 0.47 (0.27) 0.63 (0.4) 0.63 (0.4)
Median (iQr) daily no. of sABA dosesc 0.55 (0.27–0.55) 0.55 (0.27–0.55) 0.55 (0.27–0.82) 0.55 (0.27–0.82)
hospital admission, ≥1, n (%) 12 (11.5) 7 (6.7) 14 (5.1) 47 (4.3)
eD attendance, ≥1, n (%) 9 (8.7) 2 (1.9)e 5 (1.8) 25 (2.2)
Acute respiratory event, ≥1, n (%)d 89 (85.6) 89 (85.6) 142 (51.6) 568 (51.6)
risk-domain asthma control, n (%)d 15 (14.4) 15 (14.4) 68 (24.5) 272 (24.7)
Oral candidiasis, ≥1, n (%)d 3 (2.9) 0 2 (0.7) 14 (1.3)
Pneumonia, yes, n (%)d 4 (3.8) 1 (1.0) 2 (0.7) 8 (0.7)
Notes: aMatching variable. bComorbidities were defined as follows: eczema as ever-recorded diagnostic Read code + topical steroid; and rhinitis as ever-recorded diagnosis 
and/or prescription for nasal steroids. cThe daily sABA dose was calculated as the number of doses in issued prescriptions averaged over the baseline year. One sABA dose 
was two puffs (100 µg per puff). dAn acute respiratory event was defined as occurrence of 1) an asthma-related hospital admission or ED attendance or 2) an acute course 
of OCSs coded for asthma or 3) antibiotics prescribed with a lower respiratory consultation. Risk-domain asthma control was defined as follows: 1) no asthma-related 
hospital admission, eD attendance, or outpatient department attendance; 2) no acute Ocs prescription with a lower respiratory consultation; and 3) no antibiotics prescribed 
with a lower respiratory consultation. Oral candidiasis (thrush) was defined as a Read code for oral candidiasis or topical antifungal prescription definitely for treating oral 
candidiasis. Pneumonia was defined as a diagnostic Read code for pneumonia. eP=0.03 for comparison between LTRA and ICS cohorts. There were no significant differences 
between EF-particle ICS and fine-particle ICS cohorts or between LTRA and ICS cohorts for other variables.
Abbreviations: ED, emergency department; EF, extrafine; ICS, inhaled corticosteroid; IQR, interquartile range; LTRA, leukotriene receptor antagonist; OCS, oral 
corticosteroid; sABA, short-acting β-agonist.
The times to first wheezing/asthma attack were similar in 
the two comparisons (log-rank P≥0.10; Figures S7 and S8).
Discussion
We found no significant differences in the odds of wheezing/
asthma attacks during the outcome year in any of the four 
treatment comparisons, including ICS vs SABA, LTRA vs 
SABA, LTRA vs ICS, and EF-particle ICS vs fine-particle 
ICS, between matched cohorts of preschool children with two 
or more prior episodes of wheezing and/or OCS prescriptions. 
The only statistically significant difference we observed dur-
ing the outcome year is perhaps not clinically significant in 
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light of other findings and the few children affected, namely, 
2% vs 1% of children with an ED visit in the ICS vs SABA 
cohorts, respectively. These results contrast with those of 
our previous study of older children, for whom there were 
indications of better effectiveness of EF-particle ICS than 
fine-particle ICS,25 as we had found in prior adult studies.30–32
One possible explanation for our findings is that there is 
genuinely no effect of any of these agents (EF-particle ICS, 
fine-particle ICS, or LTRA) with regard to preventing wheez-
ing/asthma attacks in preschool children with intermittent 
disease. Several other explanations are possible, however. 
The mix of asthma phenotypes among preschool children in 
our large, general asthma population may preclude identify-
ing a single effective agent. Indeed, this heterogeneity could 
explain the negative results of this study, including both the 
heterogeneity of preschool wheeze as an entity and the het-
erogeneity of response to ICS and LTRA among children with 
preschool wheeze,6 evident even in relatively homogeneous 
RCT populations.9 In addition, because preschool wheeze 
is often self-limiting, spontaneous improvement over time 
could reduce the study power to detect an impact of the 
interventions. As reported in the “Results” section, in each 
of the eight cohorts, the proportions of children experiencing 
one or more wheezing/asthma attacks fell from the baseline 
year to the outcome year.
Our findings suggest that watchful waiting, obviously in 
conjunction with as-needed symptom management, may be 
the best approach for many children with preschool wheeze. 
This approach, however, should not preclude the assessment 
of several clinical factors that could suggest responsiveness 
to ICS or LTRA – especially for children who have evidence 
of symptoms between more severe episodes – in particular 
blood eosinophil count and aeroallergen sensitization, as 
well as other factors included in the modified API, namely 
physician-diagnosed atopic dermatitis, parental history of 
asthma, allergic sensitization to milk, eggs, or peanuts, and 
wheezing unrelated to colds.9,14,15 Fitzpatrick et al9 found that 
daily ICS was most likely to be efficacious for preschool 
children who had evidence of type 2 inflammation (aeroal-
lergen sensitization and elevated blood eosinophil count). In 
a recent population-based study,3 allergic rhinitis, eczema, 
and parental asthma were three readily assessed variables 
associated with asthma diagnosis by 4 years of age in chil-
dren with ever-wheeze. Finally, outcomes in another recent 
study suggested that children with the 5/5 ALOX5 promoter 
genotype may be responsive to intermittent montelukast 
Table 4 Outcome measures during 1 follow-up year for the controller therapy matched cohort comparisons: lTrA vs ics and eF-
particle ICS vs fine-particle ICS
Outcome LTRA vs ICS EF-particle ICS vs fine-particle ICS
LTRA (n=104) ICS (n=104) P-valuea EF-particle ICS  
(n=275)
Fine-particle ICS  
(n=1,100)
P-valuea
Wheezing/asthma attack, n (%)
0 57 (54.8) 63 (60.6) 0.38 176 (64.0) 734 (66.7) 0.36
1 25 (24.0) 23 (22.1) 59 (21.5) 249 (22.6)
≥2 22 (21.2) 18 (17.3) 40 (14.5) 117 (10.6)
hospital admission, n (%)
0 101 (97.1) 102 (98.1) 0.66 268 (97.5) 1,075 (97.7) 0.79
1 2 (1.9) 1 (1.0) 7 (2.5) 22 (2.0)
2 1 (1.0) 1 (1.0) 0 3 (0.3)
eD visit, n (%)
0 100 (96.2) 103 (99.0) 0.22 271 (98.6) 1,087 (98.8) 0.71
1 4 (3.8) 1 (1.0) 4 (1.4) 14 (1.0)
2 0 0 0 0
3 0 0 0 2 (0.2)
Acute Ocs prescription, n (%)
0 60 (57.7) 64 (61.5) 0.78 204 (74.2) 846 (76.9) 0.32
1 21 (20.2) 20 (19.2) 48 (17.5) 182 (16.6)
2 11 (10.6) 15 (14.4) 19 (6.9) 51 (4.6)
3 11 (10.6) 4 (3.9) 4 (1.5) 12 (1.1)
4 1 (1.0) 1 (1.0) 0 8 (0.7)
5 0 0 0 1 (0.1)
Note: aMatched cohorts were compared (for none vs ≥1 outcome) using conditional logistic regression.
Abbreviations: ED, emergency department; EF, extrafine; ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid.
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therapy (P-value for interaction =0.08).19 We were not able 
to assess these factors, as they were not evaluated in practice 
and/or recorded in the database for most children; however, 
an analysis including children with evidence of type 2 
inflammation (aeroallergen sensitization and elevated blood 
eosinophil count or FeNO) is an important topic for further 
study in future observational studies using stratified analyses 
based on atopic status.
Prior work has suggested that early suppression of lung 
growth resulting in reduced maximum lung function in 
adulthood is associated with an increased risk of develop-
ing COPD.33–37 Childhood wheezing, childhood asthma, 
and childhood respiratory infections have been identified as 
factors associated with permanently lower lung function.33,35 
While neither ICS nor LTRA therapy was associated with 
reduced odds of wheezing/asthma attacks over 1 year in this 
study, we cannot exclude the potential for long-term benefits 
of therapy on the trajectory of lung growth for some children, 
and hence a future reduction in the risk of adult conditions 
such as COPD.
We observed improvements across most end points, and 
for all treatment options, between baseline and outcome 
years. There could have been transient response to treat-
ment in subgroups of children, but we speculate that for 
many children the greatest driver of improvement was likely 
time rather than treatment. Wheezing in young children can 
result from viral infections causing swelling and narrowing 
of small airways, a condition that does not respond to ICS 
but may be less likely to occur in subsequent years as the 
lungs grow in size.
In our study, ICS therapy was not associated with lower 
odds of wheezing/asthma attacks over the outcome year as 
compared with either SABA or LTRA therapy. There could 
in theory have been some dilution of comparative effects 
because 50% of children in the two SABA cohorts and 63% 
and 69% of those in the two LTRA cohorts were prescribed 
an ICS during the outcome year. However, we found no sig-
nificant difference between matched cohorts for the time to 
first wheezing/asthma attacks after censoring children who 
had treatment failure (ie, change in therapy) before their first 
attack. Nevertheless, a pragmatic trial of patients who persist 
on their index date therapy could further elucidate this point.
In the LTRA vs ICS comparison, the fact that 69% of the 
children in the LTRA cohort were prescribed ICS in the out-
come year while only 8% of the ICS cohort were prescribed 
LTRA during the outcome year suggests that those in the 
LTRA cohort had poorer control during the outcome year. 
Alternatively, this finding could be attributed to  common 
prescribing pathways, whereby clinicians may be more likely 
to prescribe ICS to children whose symptoms do not respond 
to an LTRA than the converse (ie, prescribe LTRA to chil-
dren whose symptoms do not respond to an ICS). Overall, 
many more children in the database were initiated on ICS 
(n=11,329) than LTRA (n=335).
Our findings are consistent with previous data and con-
clusions that maintenance controller therapy is not effective 
in managing episodic wheezing in preschool children.38–40 
This study enabled us to record the occurrence of wheez-
ing/asthma episodes over a 2-year time span, longer than 
most clinical trials. Most of the study cohorts were large, 
and cohort pairs were well-matched for baseline character-
istics, as indicated by few remaining differences in baseline 
variables not used for matching. However, many eligible 
patients were excluded during the matching process, often 
at the last step when unique matched pairs were randomly 
selected and duplicate pairs were excluded; therefore, the 
cohort numbers were substantially reduced, limiting study 
power. Indeed, <9% of ICS-treated children were included 
in the ICS/SABA analysis, and the two LTRA cohorts were 
relatively small (259 and 104 children), which could have 
limited statistical power to detect differences in outcomes. 
Moreover, some characteristics of the LTRA cohort as com-
pared with the matched SABA cohort indicated more active 
disease at baseline (more antibiotics, ED visits, and repeat 
doses of OCS), although the only statistically significant 
differences were for ED visits and pneumonia, affecting few 
children and not always reliably recorded in general practice 
records. In addition, the matched LTRA/SABA cohorts were 
slightly younger than the matched ICS/SABA cohorts (mean 
2.6 vs 3.2 years), which could have influenced the findings 
in light of the time effects. Overall, our study population 
may represent children on the milder end of the spectrum, 
as the study design required excluding children prescribed 
ICS before the age of 1 and those prescribed ICS or LTRA 
during the baseline year.
 Another study limitation is that we were unable to 
ascertain whether children had persistent symptoms or were 
symptom-free between wheezing/asthma attacks. Moreover, 
the occurrence of adverse effects is not reliably recorded 
in medical records, hence not in the datasets, whereas a 
comparison of adverse occurrence associated with each 
treatment option would be useful information and constitutes 
an important area of further study. In addition, we could not 
assess medication adherence, and our study design could not 
distinguish between daily or intermittent ICS administration 
nor whether new therapy during the outcome year constituted 
a switch or add-on to existing therapy. The analyses depended 
on the quality of data recorded in primary care records, and 
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the ability to clinically characterize the children was restricted 
to data available in their medical records. For example, we 
used an ever-recorded diagnosis of eczema, present for 
38%–41% of children in each cohort, as an indicator of 
atopy. Other limitations include those common to all obser-
vational studies, including the potential for selection bias and 
unmeasured confounding factors. Moreover, it is likely that 
not all secondary care and hospital attendance information 
was captured in the longitudinal, electronic medical records 
housed at each individual’s primary care practice. Although 
prescribing information in UK electronic medical records 
is generally considered reliable,41 we cannot be certain that 
medications were taken as prescribed.
We found high levels of antibiotic prescribing, with 
50%–70% of children in each cohort prescribed at least one 
course of antibiotics during the baseline year and 35%–45% 
of children prescribed at least one course during the outcome 
year. The most recent UK pediatric audit (November 2015) 
found that 28% of preschool children presenting to hospitals 
and EDs with acute asthma/wheeze were prescribed antibi-
otics.4 These findings suggest that antibiotics are frequently 
prescribed for preschool wheeze despite the fact that most 
intermittent wheezing episodes are thought to be attributable 
to viral infections and therefore not responsive to  antibiotics.10 
Results of two studies have suggested that azithromycin 
therapy may decrease the length of episodes of lower respi-
ratory symptoms in preschool children;42,43 however, further 
study is needed before determining whether widespread use 
of azithromycin for preschool wheeze is appropriate.44
Conclusion
This large matched cohort analysis of anonymized UK medi-
cal record data found no evidence that stepping up therapy, 
compared with as-needed use of SABA, reduces wheezing/
asthma attacks in a diverse population of preschool children 
with at least two documented prior wheezing episodes. Our 
findings underscore the need for better understanding of dis-
ease patterns and better targeting of existing therapies, or new 
therapeutic modalities, as well as the need for real-world data 
on adherence, atopic status, and emerging biomarkers. In the 
absence of better tools to help target treatments, and in light of 
improved outcomes over time in all cohorts, these data suggest 
that a “wait-and-see approach” for many preschool children 
with intermittent disease may be a clinically prudent approach.
Abbreviations
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